Kidswell Bio Corporation
Q1 FY2027 Financial Summary (Japan GAAP) (Consolidated)
For the first quarter of FY2027, net sales were 1,269 million yen, down 26.2% year over year. Operating income was 216 million yen, ordinary income 203 million yen, and net income attributable to owners of the parent 197.9 million yen. For the full year, the company disclosed a range of net sales of 5,000–6,000 million yen and operating income of 100–600 million yen.
Key Figures
- Net sales: 1,269,509千円
- Operating income: 216,506千円
- Net income attributable to owners of the parent: 197,902千円
AI要約
Performance overview
This quarter progressed with two main segments: a biosimilar business and a cell therapy business. Net sales declined year over year due to the post-launch competitive environment for products such as adalimumab, but profitability improved due to strengthened supply of APIs/ formulations and cost-reduction measures. Operating income was 216 million yen, ordinary income 203.7 million yen, and net income attributable to owners of the parent 197.9 million yen, all above the previous year. The full-year outlook provides a range of net sales of 5,000–6,000 million yen and operating income of 100–600 million yen.
Financial position and outlook
Total assets were 6,130,763 thousand yen, and net assets were 1,837,447 thousand yen. The company will continue efforts to strengthen its financial base, stabilize manufacturing and delivery plans, and enhance responses to exchange rate and cost fluctuations. R&D expenditure is expected to intensify from the second quarter onward. There are no significant events affecting the continuity of the company, while note-worthy attention is drawn to potential increases in funding needs.
Kidswell Bio Company
Company overview · Stock price · Financial data · All IR
